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tious anemia virus (EIAV), a lentivirus, as 
a transfer vector for the striatal expression 
of key enzymes involved in the production 
of dopamine. The second one is based on 
the use of adeno-associated vectors type 2 
for the striatal expression of neurturin, a 
dopaminergic trophic factor (Marks et al., 
2008). Whereas these two approaches aim 
primarily at ameliorating the symptoms, no 
trial has attempted to correct the cause of 
the disease. Parkinson’s disease constitutes 
an ideal case for gene therapy as its target, 
the substantia nigra pars compacta, is well 
defined and contains a small number of 
cells to be infected (less than one million 
dopaminergic nigral neurons). It remains to 
be elucidated which gene should be inves-
tigated for preventing neuronal demise. 
The first genes that come to mind are 
those involved in recessive forms of famil-
ial Parkinson’s disease, namely parkin and 
Our molecular understanding of neurode-
generative diseases has made remarkable 
progress during the last decade. The genetic 
cause of diseases such as Huntington’s or 
spinal muscular atrophy has been unraveled. 
Numerous gene defects have been identi-
fied for the familial forms of amyotrophic 
lateral sclerosis, fronto-temporal demen-
tia, Alzheimer’s and Parkinson’s disease. In 
parallel, lentiviral viral vectors and adeno-
associated vectors have been developed to 
the point that they can be safely considered 
for in vivo gene therapy clinical trials. Based 
on encouraging results obtained in primate 
models of Parkinson’s disease (Jarraya et al., 
2009), two clinical trials have been recently 
performed. The first one used equine infec-
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figure 1. (A) ICV injection of AAV6-GFP results in widespread GFP expression across the brain and spinal cord. High magnification indicating transduction of (B) Purkinje cells of 
the cerebellum and (C) motor neurons of the spinal cord ventral horn. Scale bar = 100 μm.
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pink1, whose overexpression may compen-
sate for a loss of function. The small number 
of patients and the slow evolution of the 
disease question this approach. Whereas the 
down-regulation of α-synuclein (α-Syn) 
using RNAi technology seems a promising 
approach, the recent observation in rodents 
that α-Syn silencing leads to a loss of nigral 
dopaminergic neurons in rodents has raised 
concerns about this strategy (Gorbatyuk 
et al., 2009). Other neurodegenerative dis-
eases, such as Huntington’s or Alzheimer’s 
disease, will require infection of a large 
number of spread neurons – a presently 
unresolved technical problem. 
The most promising diseases may para-
doxically be those affecting motoneurons. 
Whereas Foust et al. (2009) have reported 
that the intravascular AAV-9 preferen-
tially targets neonatal and adult astrocytes, 
Chris Towne in our laboratory has recently 
observed that the intrathecal injection of 
AAV-6 results in a very large number of 
motoneurons infected all along the spi-
nal cord of rodents (Figure 1). Promising 
results have been observed in mouse models 
of spinal muscular atrophy by the overex-
pression of the smn gene. However, scale-up 
of the system to primates is required before 
moving to the clinic. Familial amyotrophic 
lateral sclerosis caused by mutations in the 
copper zinc superoxide dismutase could 
also benefit from this approach. 
While basic science will provide us with 
more genes to test, we need to continue our 
quest to further improve our viral vectors 
so that they can accommodate larger genes, 
diffuse over longer distances and infect a 
specific subpopulation of nerve cells. The 
rationale to use gene therapy for treating 
the cause of neurodegenerative is sound. We 
just need more sweat and hard work. 
